Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
- 31 July 2009
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 14 (13-14), 690-697
- https://doi.org/10.1016/j.drudis.2009.05.002
Abstract
No abstract availableKeywords
This publication has 123 references indexed in Scilit:
- Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: The therapeutic potentials for schizophreniaPharmacology & Therapeutics, 2008
- Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implicationsBiological Psychiatry, 2008
- Synaptic integration and plasticity of new neurons in the adult hippocampusThe Journal of Physiology, 2008
- Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: Role of corticosterone-mediated apical dendritic atrophyProceedings of the National Academy of Sciences of the United States of America, 2008
- The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fearLearning & Memory, 2008
- Improved cognitive function in schizophrenia after one year of cognitive training and vocational servicesSchizophrenia Research, 2007
- Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fearLearning & Memory, 2007
- VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressantsProceedings of the National Academy of Sciences of the United States of America, 2007
- Probing the Pathophysiology of Auditory/Verbal Hallucinations by Combining Functional Magnetic Resonance Imaging and Transcranial Magnetic StimulationCerebral Cortex, 2007
- Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patientsCurrent Opinion in Psychiatry, 2006